This is a recent post with his input and they do raise some good points.
The Biden Administration’s strategy to universally vaccinate in the middle of the pandemic is bad science and badly needs a reboot.
www.washingtontimes.com
What I don't see them address is mutations in nature. The Delta variant is affecting the unvaccinated far more than it is the vaccinated. I haven't seen any evidence to suggest the Delta variant is a mutation derived from vaccinated individuals, but I am not saying it isn't.
They also aren't addressing the strain on the healthcare system, which is what I have always been focused on. Sure we can let people get sick...but if that number of people gets too high and we run out of hospital space then people have no supportive/skilled care and have a greater chance of death.
When he mentioned fluvoxamine and apixiban for COVID I raised an eyebrow.
The Apixiban study is still in progress, and I see no pre-published results that would indicate it is anything more than a prophylactic anticoagulant for patients at risk of clots. We use lots of drugs in this way for many conditions.
https://clinicaltrials.gov/ct2/show/NCT04746339
Fluvoxamine may be a causal relationship...it appears to show an unknown relationship between administration and clinical deterioration outcomes. The sample size was very small, although statistically significant. More research is needed.
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects vs placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction–confirmed mild coronavirus disease...
jamanetwork.com